We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
-8.87%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$2.94B
AUM Growth
-$1.55B
Cap. Flow
-$1.01B
Cap. Flow %
-34.35%
Top 10 Hldgs %
43.7%
Holding
135
New
15
Increased
7
Reduced
68
Closed
31

Top Buys

Rank Stock Value
1
GLUE icon
Monte Rosa Therapeutics
GLUE
+$65.1M
2
BMEA icon
Biomea Fusion
BMEA
+$56M
3
JBIO
Jade Biosciences
JBIO
+$46.4M
4
RAIN
Rain Oncology Inc. Common Stock
RAIN
+$46M
5
AMAM
Ambrx Biopharma Inc
AMAM
+$42.4M

Top Sells

Rank Stock Value
1
CCCC icon
C4 Therapeutics
CCCC
+$76.5M
2
APLS
Apellis Pharmaceuticals
APLS
+$52.4M
3
NVAX icon
Novavax
NVAX
+$45.3M
4
CCXI
ChemoCentryx, Inc.
CCXI
+$43.6M
5
OMER icon
Omeros
OMER
+$35.2M

Sector Composition

Rank Sector Weight
1 Healthcare 86.38%
2 Financials 0.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRDN icon
76
Viridian Therapeutics
VRDN
$2.49B
$6.27M 0.21%
342,962
-116,182
-25% -$1.99M
MRUS
77
DELISTED
Merus
MRUS
$6.01M 0.2%
285,096
-64,904
-19% -$1.43M
LENZ
78
LENZ Therapeutics
LENZ
$164M
$5.93M 0.2%
+29,022
New +$5.05M
AVEO
79
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$5.89M 0.2%
893,500
-606,500
-40% -$4.18M
DCPH
80
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$5.29M 0.18%
144,439
-55,561
-28% -$2.15M
AKUS
81
DELISTED
Akouos Inc
AKUS
$4.95M 0.17%
394,500
-105,489
-21% -$1.43M
SRNE
82
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$4.84M 0.16%
500,000
-2,250,000
-82% -$17.9M
DNTH icon
83
Dianthus Therapeutics
DNTH
$6.15B
$4.68M 0.16%
29,888
-7,612
-20% -$1.4M
MLTX icon
84
MoonLake Immunotherapeutics
MLTX
$1.53B
$4.45M 0.15%
430,000
– –
QTNT
85
DELISTED
Quotient Limited Ordinary Shares
QTNT
$4.38M 0.15%
30,083
-7,417
-20% -$1.19M
TBPH icon
86
Theravance Biopharma
TBPH
$877M
$4.36M 0.15%
300,000
-250,000
-45% -$4.69M
DTIL icon
87
Precision BioSciences
DTIL
$191M
$4.34M 0.15%
11,551
– –
FVAM
88
DELISTED
5:01 Acquisition Corp
FVAM
$3.99M 0.14%
400,000
-100,000
-20% -$1M
GTH
89
DELISTED
Genetron Holdings Limited ADS
GTH
$2.68M 0.09%
44,289
-55,711
-56% -$3.44M
AUTL
90
Autolus Therapeutics
AUTL
$532M
$2.6M 0.09%
392,167
-30,000
-7% -$186K
OBIO icon
91
Orchestra BioMed
OBIO
$249M
$2.45M 0.08%
240,000
-560,000
-70% -$5.79M
EIGR
92
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$2.43M 0.08%
9,500
-3,833
-29% -$957K
BCEL
93
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$2.33M 0.08%
273,500
-20,000
-7% -$205K
TCDA
94
DELISTED
Tricida, Inc. Common Stock
TCDA
$1.85M 0.06%
427,975
– –
GOSS icon
95
Gossamer Bio
GOSS
$87.2M
$1.61M 0.05%
198,382
-650,000
-77% -$5.64M
SWTX
96
DELISTED
SpringWorks Therapeutics
SWTX
$1.24M 0.04%
15,000
-110,000
-88% -$8.35M
ORTX
97
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$1.13M 0.04%
25,665
– –
XFOR icon
98
X4 Pharmaceuticals
XFOR
$393M
$676K 0.02%
3,466
– –
CRDF icon
99
Cardiff Oncology
CRDF
$74.7M
$637K 0.02%
95,720
-54,280
-36% -$460K
NERV icon
100
Minerva Neurosciences
NERV
$207M
$570K 0.02%
30,718
+5,718
+23% +$123K
2 3
4
5 6

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.79% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

Cormorant Asset Management's Q2 2021 Portfolio in Review

As of Q2 2021, Cormorant Asset Management held 135 positions worth $2.94B, down 34% from $4.49B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Cormorant Asset Management withdrew a net $1.01B in Q2 2021, closing 31 positions and reducing 68 holdings. Its most notable exit was Novavax, an estimated $45.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 75% a quarter earlier, followed by Financials.

Against the trend, Cormorant Asset Management opened a new position in Monte Rosa Therapeutics worth $69.5M.

  • Cormorant Asset Management's largest Q2 2021 buy was Monte Rosa Therapeutics: 3,193,973 shares worth $69.5M.
  • Cormorant Asset Management added most to Revolution Medicines in Q2 2021, an estimated $28.4M increase.
  • Cormorant Asset Management's biggest Q2 2021 reduction was C4 Therapeutics, cutting an estimated $76.5M.
  • Cormorant Asset Management fully exited Novavax in Q2 2021, selling an estimated $45.3M.
  • Cormorant Asset Management's ten largest holdings make up 44% of its $2.94B portfolio in Q2 2021.
  • Cormorant Asset Management opened 15 new positions and closed 31 in Q2 2021.
  • Cormorant Asset Management's portfolio value fell 34% quarter-over-quarter to $2.94B.

Based on Cormorant Asset Management's 13F filing for Q2 2021, filed 16 Aug 2021.